VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | SWOG S1310: trametinib vs 5-FU/capecitabine in refractory advanced biliary cancer

VJOncology is committed to improving our service to you

Richard Kim

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, outlines results from a Phase II trial evaluating single agent MEK inhibitor trametinib versus 5-fluorouracil (5-FU) or capecitabine in refractory advanced biliary cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter